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ABSTRACT
Safrole from sassafras oil (Ocotea pretiosa Mez., Lauraceae), is an abundant natural product showing interesting functionality and chemical structure. Starting 
from safrole, nine derivatives were prepared and assessed for antiproliferative effect using different human cell lines. The in vitro growth inhibition assay was 
based on the sulphorhodamine dye to quantify cell viability.  Some safrole derivatives, (2E)-3-(3’,4’-methylenedioxi)phenyl acrylaldehyde (3) and 4-allyl-5-
nitrobenzene-1,2-diol (4) presented better antiproliferative effect than the parent compound on two breast cancer cell lines (MCF-7 and MDA-MB-231) and one 
human colorectal cancer cell line (DLD-1) with IC50 values of 55.0 + 7.11 µM, 37.5 + 2.65 µM and 44.0 + 6.92 µM, respectively, without toxicity towards dermal 
human fibroblast (DHF cells). 
Keywords: Antiproliferative activity, safrole derivatives, synthesis. 
INTRODUCTION
Cancer is the largest single cause of death in men and women. Recently, 
resistance to anticancer drugs has been observed. Therefore, the research and 
development of more effective and less toxic drugs by the pharmaceutical 
industry has become necessary. Many substances derived from dietary or 
medicinal plants are known to be effective and versatile chemopreventive and 
antitumoral agents in a number of experimental models of carcinogenesis. 
Safrole, from sassafras oil (Ocotea pretiosa Mez., Lauraceae), is an 
abundant natural product showing interesting functionality and chemical 
structure. The methylenedioxy unit, present in safrole, can be identified in 
the clinical antitumour agents etoposide and teniposide1 and lignan lactone 
podophylotoxin2. 
We have shown what eugenol and this derivates present antioxidant 
capacity evaluated by the DPPH (1,1-diphenyl-2-picrylhydrazil) and ORAC 
assays. Eugenol derivatives exhibited a haemolysis percentage lower than 1%, 
which indicate very low toxicity for red blood cell membranes.3 In vitro studies 
carried out on two human cancer cell lines: DU-145 (androgen-insensitive 
prostate cancer cells) and KB (oral squamous carcinoma cells) measuring cell 
viability by the tetrazolium salt assay. Lactic dehydrogenase (LDH) release 
was also measured to evaluate cell toxicity as a result of cell disruption, 
subsequent to membrane rupture. In the examined cancer cells, all compounds 
showed cell-growth inhibition. The results indicate that the compounds 5-allyl-
3-nitrobenzene-1,2-diol and 4-allyl-2-methoxy-5-nitrophenyl acetate were 
significantly more active than eugenol (p < 0.001), with IC50 values of 19.02 
x 10-6 and 21.5 × 10-6 mol L-1, respectively, in DU-145 cells and 18.11 × 
10-6 and 21.26 × 10-6 mol L-1, respectively, in KB cells, suggesting that the 
presence of nitro and hydroxyl groups could be important in the activity of these 
compounds. In addition, our results suggest that apoptosis is induced in KB and 
DU-145 cells. In fact, in our experimental conditions, no statistically significant 
increase in LDH release was observed in cancer cells treated with eugenol and 
its analogues.4 This results suggest that structural analogous of eugenol bearing 
a nitro group and a hydroxyl group can present antiproliferative/cytotoxic 
effect on cells.
Antiproliferative screening in vitro provide preliminary data to select 
compounds with potential antineoplastic properties. Safrole (1) and its synthetic 
derivatives (2-8) were tested in vitro for antiproliferative effect on two human 
tumor breast cancer cell lines (MDA-MB-231, MCF-7), one human colorectal 
cancer cell line (DLD-1) and one dermal human fibroblast cell line (DHF). 
The  in vitro growth inhibition assay used was based on sulphorhodamine dye, 
widely used to quantify cell viability.
EXPERIMENTAL 
General 
Safrole was obtained commercially from Sigma-Aldrich, and other 
chemical reagents were purchased (Merck or Aldrich) with the highest purity 
commercially available and were used without previous purification. IR spectra 
were obtained by using KBr pellets or thin films in a Nicolet Impact 420 
spectrometer. Frequencies are reported in cm-1. Low resolution mass spectra 
were recorded on a Shimadzu QP-2000 spectrometer at 70eV ionising voltage 
and are given as m/z (% rel. int.) 1H, 13C (DEPT 135 and DEPT 90). Some 
spectra were recorded in CDCl3 solutions and were referenced to the residual 
peaks of CHCl3, d=7.26 ppm and d=77.0 ppm for 
1H and 13C, respectively; 
CD3COCD3 solutions were referenced to the residual peaks of CH3COCH3, 
d=2.04 ppm and d=29.8 ppm for 1H and 13C, respectively, on a Bruker Avance 
400 Digital NMR spectrometer operating at 400.1MHz for 1H and 100.6 MHz 
for 13C. Chemical shifts are reported in d ppm and coupling constants (J) are 
given in Hz. Silica gel (Merck 200-300 mesh) was used for C.C. and silica gel 
plates HF-254 for TLC. TLC spots were detected by heating after spraying 
with 25% H2SO4 in H2O.
Synthesis 
4-allyl-5-nitro-1,2-methylenedioxibenzene (2) and (2E)-3-(3’,4’-
methylenedioxi)phenyl acrylaldehyde (3) 
To a solution of safrole 1 in acetic acid (8 mL) at -5 °C (2.0 g, 12.3 mmol) a 
solution of nitric acid and sulphuric acid at -5 °C (10:1 ratio; 2.5 mL) was added 
dropwise. The mixture at -10 °C was stirred for 4 h, taken up in water (10mL) 
and extracted with ethyl acetate (EtOAc, 3 x 50 mL). The organic layer was 
washed to neutrality with a saturated NaHCO3 solution, dried over MgSO4 and 
taken to dryness under reduced pressure. The residue was chromatographed on 
a silica gel column with mixtures of petroleum ether (PE)/EtOAc of increasing 
polarity (19.8:0.2→17.8:2.2). After TLC comparison, 1.86 g (75.0%) of 
compound 2 and 0.11 g (5.2%) of compound 3 were obtained. Compound 
2, red viscous oil; IR (cm-1): 3081 (=C-H); 2912 (C-H); 1616 (C=C); 1523 
(-NO2); 1480 (C=C); 1421 (-CH2); 1328 (N=O); 1257 (C-O-C); 927 (-C-O-C-); 
817 (-C-H). M.S. (m/z, %):208 (2.8); 207 (23.0); 190 (100); 177 (21.0); 176 
(17.5); 173 (50.2); 162 (16.9); 160 (23.0); 132 (29.7); 103 (24.9); 102 (51.3); 
77 (43.9); 76 (22.6); 53 (16.2); 51 (19.4). 1H NMR: 7.49 (s, 1H, H-6); 6.76 (s, 
1H, H-3); 6.09 (s, 2H, OCH2O); 5.95 (ddt, 1H, 1H, J=17.0, 10.3 and 6.5 Hz, 
H-2’); 5.10 (m, 2H, H-3’); 3.65 (d, 2H, J=4.0 Hz, H-1’); 13C NMR: 151.7 (s, 
C-2); 146.5 (s, C-5 and s, C-1); 135.2 (d, C-2’); 132.2 (s, C-4); 117.0 (t, C-3’); 
110.4 (d, C-3); 105.7 (t, OCH2O); 102.7 (d, C-6); 37.6 (t, C-1’); 
Compound 3, yellow viscous oil; IR (cm-1): 2913 (C-H); 2825 (C-H); 
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1724 (C=O); 1663 (C=C-C=O); 1610 (C=C); 1492 (C=C); 1254 (C-O-C); 938 
(-C-O-C-). 1H NMR: 9.65 (d, 1H, J=7.7 Hz, H-3’); 7.38 (d, 1H, J=15.8 Hz, 
H-1’); 7.08 (dd, 2H, J=1.7 and J=8.6 Hz, H-5); 7.06 (d, 1H, J=1.7 Hz, H-3); 
6.86 (d, 1H, J=8.6 Hz, H-6); 6.56 (dd, 1H, J=7.7 Hz and J=15.8 Hz, H-2’), 6.04 
(s, 2H, OCH2O); 
13C NMR: 193.9 (d, CHO); 152.9 (d, C-1’); 150.1 (s, C-1); 
148.5 (s, C-2); 128.3 (s, C-4); 127.0 (d, C-2’); 124.7 (d, C-5); 107.7 (d, C-3); 
107.3 (d, C-6); 101.0 (t, OCH2O). 
4-allyl-5-nitrobenzene-1,2-diol (4) 
To a cold suspension of AlCl3 (0.68 g, 5.1 mmol) in CH2Cl2 (5.0 mL) 
at 0 °C (under N2 atmosphere) a solution at -5 °C of 2 (0.30 g, 1.5 mmol) in 
CH2Cl2 (7.0 mL) was slowly added. The resulting mixture was stirred for 2 h 
at -10 °C. Cold water was added to the mixture (approx. 10mL). The resulting 
mixture was stirred for 18 h at room temperature under nitrogen. The reaction 
mixture was poured into brine solution and extracted with EtOAc (3 x 100 
mL). The organic layer was washed with brine then dried over MgSO4, filtered, 
evaporated and re-dissolved in 5 mL of acetone. After that, it was adsorbed 
on silica, chromatographed by CC eluting with mixtures of petroleum ether/
EtOAc of increasing polarity (17.0:3.0→15.0:5.0) to give 4, an orange oil (0.16 
g, 57.4% ). IR (cm-1): 3311 (O-H); 2907 (C-H); 1598 (C=C); 1526 (NO2); 1495 
(C=C); 1429 (-CH2); 1326 (N=O); 1275 (C-O); 1045 (-C-OH); 809 (-C-H). 
1H NMR: 8.99 (bs, 2H, OH); 7.57 (s, 1H, H-6); 6.84 (s, 1H, H-3); 5.95 (ddt, 
1H, 1H, J=17.0, 10.3 and 6.5 Hz, H-2’, H-2’); 5.03 (m, 2H, H-3’); 3.61 (d, 
2H, J=6.4 Hz, H-1’); 13C NMR: 151.3 (s, C-2); 144.4 (s, C-1); 141.4 (d, C-5); 
137.1 (d, C-2’); 129.7 (s, C-4); 118.4 (t, C-3’); 116.3 (d, C-3); 113.0 (d, C-6); 
37.6 (t, C-1’).
3-(3’,4’-methylenedioxi)phenyl propan-1-ol (5) and 
1-(3’,4’-methylenedioxi)phenyl propan-2-ol (6) 
The compound 1 (1.0 g, 6.2 mmol) to -5 °C, under N2 atmosphere was 
slowly hydroborated with a 2.0 M solution of BH3·DMS/THF (0.67 mL) at 
-10 °C for 15 min was added dropwise. Then the mixture was stirred at room 
temperature for 1 h. The resulting organoborane is oxidized with sodium 
perborate (0.95 g, 6.2 mmol) and water (100 mL). The mixture was stirred 
at room temperature for 2 h. Then, it was extracted with portions of ethyl 
ether (4 x 50 mL) and the layers were separated. The organic layer was dried 
over MgSO4, filtered, evaporated and re-dissolved in 5 mL of CH2Cl2. It was 
adsorbed on silica, chromatographed by CC eluting with mixtures of petroleum 
ether/EtOAc of increasing polarity (18.8:1.2→17.6:2.4). Then two fractions 
were obtained: fraction I (0.66 g (59.4%) of compound 5) and fraction II (12 
mg (1.1%) of isomer compound 6). Compound 5, yellow viscous oil; IR (cm-
1): 3330 (O-H); 2909 (C-H); 1495 (C=C); 1439 (-CH2); 1245 (C-O-C); 1039 
(-C-OH); 932 (C-O-C); 811 (-C-H). M.S. (m/z, %): 181 (6.2); 180 (51.6); 
136 (51.2); 135 (100); 119 (5.4); 106 (9.5); 105 (7.8); 104 (5.1); 91 (10.5); 78 
(7.1); 77 (19.7); 65 (7.3); 51 (8.6). 1H NMR: 6.73 (d, 1H, J=7.6 Hz, H-6); 6.69 
(d, 1H, J=1.4 Hz, H-3); 6.64 (dd, 1H, J=1.4 and J=7.6 Hz, H-5); 5.91 (s, 2H, 
OCH2O); 3.65 (t, 2H, J=6.4 Hz,     H-3’); 2.62 (t, 2H, J=7.4 Hz, H-1’); 1.84 
(dt, 2H, J=6.4 and J=15.2 Hz, H-2’); 1.56 (bs, 1H, OH); 13C NMR: 147.5 (s, 
C-2); 145.6 (s, C-1); 135.6 (s, C-4); 121.1 (d, C-5); 108.8 (d, C-6); 108.1 (d, 
C-3); 100.7 (t, OCH2O); 62.1 (t, C-3’); 34.4 (t, C-1’); 31.7 (t, C-2’). Compound 
6, yellow viscous oil; IR (cm-1): 3411 (O-H); 2910 (C-H); 1495 (C=C); 1439 
(-CH2); 1367 (CH3); 1245 (C-O-C); 1036 (-C-OH); 935 (C-O-C); 803 (-C-
H). 1H NMR: 6.77 (d, 1H, J=7.8 Hz, H-6); 6.71 (d, 1H, J=1.5 Hz, H-3); 6.65 
(dd, 1H, J=1.5 and J=7.8 Hz, H-5); 5.93 (s, 2H, OCH2O); 3.96 (m, 1H, H-2’); 
2.71 (dd, 1H, J=4.7 and J=13.6 Hz, H-1’a) 2.59 (dd, 2H, J=8.1 and J=13.6 Hz, 
H-1’b); 1.6 (bs, 1H, OH); 1.23 (d, 3H, J=6.2 Hz, H-3’); 
13C NMR: 147.8 (s, 
C-2); 146.2 (s, C-1); 132.2 (s, C-4); 122.3 (d, C-5); 109.7 (d, C-6); 108.3 (d, 
C-3); 100.9 (t, OCH2O); 68.9 (d, C-2’); 45.4 (t, C-1’), 22.7 (c, C-3’).
3-(3’,4’-methylenedioxi-6’-nitro)phenyl propan-1-ol (7) and 
1-(3’,4’-methylenedioxi-6-nitro)phenyl propan-2-ol (8)
Some 0.30 g (1.5 mmol) of compound 2 at -5 °C  under N2 atmosphere was 
hydroborated with a 2.0 M solution of BH3·DMS/THF (0.27 mL) at -10 °C for 
15 min. The reagent was added dropwise and the mixture was stirred at room 
temperature for 1 h. The resultant organoborane was oxidized with sodium 
perborate solution (0.28 g, 1.5 mmol) in water (100 mL). The mixture was 
stirred at room temperature for 2 h and then extracted with ethyl ether (Et2O, 
4 x 50 mL). The organic layer was dried over MgSO4, filtered and taken to 
dryness. The residue was adsorbed on silica gel and chromatographed by CC 
eluting with mixtures of PE/EtOAc of increasing polarity (16.0:4.0→14.0:6.0). 
Two fractions were obtained: 0.17 g (53.1%) of compound 7 and 7.8 mg 
(2.4%) of compound 8. Compound 7, dark yellow solid, mp (85.9-87.9°C); IR 
(cm-1): 3211 (O-H); 2907 (C-H); 1613 (C=C); 1521 (NO2); 1419 (-CH2); 1337 
(N=O); 1260 (C-O-C); 1045 (-C-OH); 922 (C-O-C); 825 (-C-H). 1H NMR: 
7.46 (s, 1H, H-6); 6.76 (s, 1H, H-3); 6.08 (s, 2H, OCH2O); 3.71 (t, 2H, J=6.2 
Hz, H-3’); 2.96 (dd, 2H, J=6.4 and J=8.6 Hz, H-1’); 1.90 (m, 2H, H-2’) 1.50 
(bs, 1H, OH); 13C NMR: 151.7 (s, C-2); 146.3 (s, C-1); 142.8 (s, C-5); 134.4 
(s, C-4); 110.6 (d, C-3); 105.7 (d, C-6); 102.7 (t, OCH2O); 62.0 (t, C-3’); 33.4 
(t, C-2’); 30.1 (t, C-1’). Compound 8, dark yellow solid, mp (92.6-94.1°C); 
IR (cm-1): 3241 (O-H); 2921 (C-H); 1620 (C=C); 1515 (NO2); 1481 (-CH2); 
1378 (-CH3); 1325 (N=O); 1258 (C-O-C); 1031 (-C-OH); 921 (C-O-C); 866 
(-C-H). 1H NMR: 7.50 (s, 1H, H-6); 6.80 (s, 1H, H-3); 6.09 (d, 2H, J=0.6 Hz, 
OCH2O); 4.11 (m, 1H, H-2’); 3.14 (dd, 1H, J=3.9 and J=13.5 Hz, H-1’a); 2.88 
(dd, 1H, J=8.3 and J=13.5 Hz, H-1’b); 1.59 (bs, 1H, OH); 1.31 (d, 3H, J=6.2 
Hz, H-3’); 13C NMR: 151.5 (s, C-2); 146,7 (s, C-5 and s, C-1); 131.2 (s, C-4); 
111.6 (d, C-3); 105.7 (t, OCH2O); 102.8 (d, C-6); 68.4 (d, C-2’); 42,9 (t, C-1’), 
23.7 (c, C-3’).
4-allyl-5-nitro-1,2-phenylene diacetate (9)
To a solution of 4 (0.38 g, 1.92 mmol) in dry CH2Cl2 (60 mL), DMAP 
(3.75 mg) and Ac2O (0.36 mL, 3.84 mmol) were added and the mixture was 
stirred at room temperature for 2 h. A cooled solution of 10% KHSO4 (approx. 
50mL) was then added to this mixture. The watery layer was discarded 
and the organic layer was washed to neutrality with a saturated solution of 
NaHCO3 and water. Then it was dried over MgSO4, filtered, evaporated and 
re-dissolved in 5 mL of CH2Cl2. Subsequently, it was adsorbed on silica and 
chromatographed by CC with petroleum ether/EtOAc mixtures of increasing 
polarity (19.8:0.2→16.4:3.6) to give 9, (0.50 mg, 94.3% ), a dark yellow solid, 
mp (62.0-63.7°C); IR (cm-1): 3083 (=C-H); 2938 (C-H); 1779 (C=O); 1639 
(C=C); 1527 (C=C); 1370 (CH3); 1272 (C-O-C). M.S. (m/z, %): 237 (18.4); 
220 (25.2); 195 (48.1); 179 (12.9); 178 (100); 165 (40.1); 164 (21.8); 161 
(25.0); 149 (11.3); 147 (13.3); 91 (9.5); 65 (10.4). 1H NMR: 7.87 (s, 1H, H-6); 
7.21 (s, 1H, H-3); 5.92 (ddt, 1H, J=17.1, 10.2 and 6.6 Hz, H-2’); 5.12 (m, 2H, 
H-3’); 3.67 (d, 2H, J=6.6 Hz, H-1’); 2.30 (s, 6H, CH3). 
13C RMN: 167.4 (s, 
2xCH3CO); 145.7 (s, C-5); 145.5 (s, C-2); 140.3 (s, C-1); 134.2 (t, C-2’); 134.0 
(s, C-4); 126.2 (d, C-3); 120.6 (t, C-3’); 117.9 (d, C-6); 36.5 (t, C-1’); 20.4 (c, 
2xCH3CO).
3-( 3’,4’-methylenedioxi-6-nitro)phenylpropyl acetate (10)
To a solution of 7 (97.8 mg, 0.43 mmol) in dry CH2Cl2 (30 mL), DMAP 
(0.98 mg) and Ac2O (40.7 μL, 0.43 mmol) were added and the mixture was 
stirred at room temperature for 2 h. A cooled solution of 10% KHSO4 (50 mL 
approx) was then added to this mixture. The watery layer was discarded and 
the organic layer was washed to neutrality with a saturated solution of NaHCO3 
and water. It was dried over MgSO4, filtered, evaporated and re-dissolved in 5 
mL of CH2Cl2 and adsorbed on silica, chromatographed by CC and eluting with 
petroleum ether/EtOAc mixtures of increasing polarity (19.8:0.2→19.0:1.0) to 
give 10, an dark yellow oil (110.4 mg, 95.1% ). IR (cm-1): 2778 (C-H); 1735 
(C=O); 1619 (C=C); 1516 (NO2); 1425 (-CH2); 1379 (CH3); 1330 (N=O); 1260 
(C-O-C); 1255 (C-O-C); 928 (C-O-C); 817 (-C-H). M.S. (m/z, %): 208 (16.0); 
191 (13.6); 190 (100); 189 (14.5); 178 (23.1); 173 (9.2); 163 (19.9); 148 (13.7); 
136 (13.3); 135 (13.1); 132 (15.7); 104 (9.9); 77 (12.2). 1H NMR: 7.43 (s, 1H, 
H-6); 6.69 (s, 1H, H-3); 6.05 (s, 2H, OCH2O); 4.07 (t, 2H, J=6.3 Hz, H-3’); 
2.89 (m, 2H, H-1’); 2.03 (s, 3H, CH3); 1.93 (m, 2H, H-2’). 
13C NMR: 170.4 (s, 
CH3CO); 151.6 (s, C-2); 146.3 (s, C-1); 142.6 (s, C-5); 133.5 (s, C-4); 110.6 
(d, C-3); 105.6 (t, OCH2O); 102.7 (d, C-6); 63.4 (t, C-3’); 30.5 (t, C-2’); 29.3 
(t, C-1’); 20.8 (c, CH3CO).
Cell Culture 
The cell cultures used were obtained from American Type Culture 
Collection (Rockville, MD, USA). Breast cancer cell lines (MDA-MB-231, 
MCF-7), a colorectal cancer cell line (DLD-1) and human dermal fibroblast 
(DHF) were grown in DMEM-F12 medium containing 10% fetal calf serum 
(FCS), 100 IU/mL penicillin, 100 µg/mL streptomycin and 1 mM L-glutamine. 
Cells were seeded into 96 well microtiter plates in 100 µL at plating density of 
3x103cells/well. After 24 h incubation at 37°C (under a humidified 5% carbon 
dioxide atmosphere to allow cell attachment) the cells were treated with different 
concentrations of safrole and derivatives (0-100 µM) and daunorubicin (0.05-
50 µM) and incubated for 72 h under the same conditions. Stock solutions of 
compounds were prepared in ethanol and the final concentration of this solvent 
was kept constant at 1%. Control cultures received 1% ethanol alone. 
Cell viability was determined by the sulforhodamine B assay according 
to Skehan et al. 19905 with some modifications6. Briefly, at the end of drug 
exposure, cells were fixed with 50% trichloroacetic acid at 4°C (TCA final 
concentration 10%). After washing with destilled water, cells were stained 
with 0.1% sulforhodamine B (Sigma-Aldrich, St. Louis, MO), dissolved in 
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1% acetic acid (50µL/well) for 30 min, and subsequently washed with 1% 
acetic acid to remove unbound stain. Protein-bound stain was solubilized with 
100µL of 10mM unbuffered Tris base. The cell density was determined using 
a fluorescence plate reader (wavelength 540nm). Values shown, are the mean + 
SD of three independent experiments in triplicate. 
RESULTS AND DISCUSSION
Synthesis Nitrosafrol (2) obtained under standard conditions7-10 (HNO3/
H2SO4/HAc) afforded the nitro compound 2 and aldehyde 3 with 75.0% and 
5.2% yields respectively (scheme 1). Oxidative hydroboration of the side 
chain of nitrosafrol led to an alcohol at C-3’. Nitrosafrol was oxidized using 
BH3·DMS/THF/NaBO3·4H2O/H2O as previously described for other alkenes 
and alkynes11. The primary alcohol 7 was obtained with a 53.1% w/w yield and 
the secondary alcohol 8 with 2.4% yield (scheme 1).
All the compounds were characterized mainly by NMR, IR and MS 
spectral data. In the 1H NMR spectrum of nitrosafrol 2, two signals at d=7.49 
(s, 1H); 6.76 (s, 1H) were assigned to H-6 and H-3 respectively. In the 13C 
NMR spectrum the signals of C-5 and C-1 were observed at d=146.5 ppm for 
a pair of overlapping quaternary carbons which corresponds to a C-5 linked to 
the nitro group. 
In the IR spectrum of compound 3, the absorption at 1724 cm-1 was 
assigned to an aldehyde carbonyl group, whereas in the 1H NMR spectrum the 
signal at d=9.65 (d, 1H, J=7.7 Hz) was assigned to an aldehyde associated to 
the signals at d=7.38 (d, 1H, J=15.8 Hz) and 6.56 (dd, 1H, J=7.7 Hz and J=15.8 
Hz) corresponding to an α, β unsaturated system (H-2’ and H-1’). Cleavage of 
the methylenedioxy ring of nitrosafrol took place during the conversion into 
the catechol 4 (57.4% yield) using the AlCl3/CH2Cl2/H2O method12-15. In the 
1H NMR spectrum, the absence of the methylenedioxy singlet between 5.90-
6.05 ppm confirmed the presence of catechol coupled with a broad signal at 
d=8.99 (brs, 2H). The MS spectrum from the diacetate derivative 9 showed 
two peaks at m/z 220 (25.2%) and 161 (25.0%) attributed to the loss of two 
acetate groups.
Oxidative hydroboration of the side chain in safrole 1 was carried out 
to obtain the alcohol  at C-3’ using the BH3·DMS/THF/NaBO3·4H2O/H2O 
method. As in the previous oxidation, the primary alcohol 5 was obtained with 
a 59.4% and the secondary alcohol 6 with 1.1%w/w yield11,16-18 (scheme 1). In 
the 1H NMR spectrum of compound 5, three signals at d=3.65 (t, 2H, J=6.4 
Hz); 2.62 (t, 2H, J=7.4 Hz) and 1.84 (dt, 2H, J=6.4 and J=15.2 Hz) are in 
agreement with the saturated side chain. In the 13C NMR spectrum, the three 
CH2 signals at 62.1; 34.4 and 31.7 ppm were to assigned at C-3’, C-1’ and C-2’ 
respectively and the signal at d = 62.1 ppm confirms the presence of primary 
carbinolic carbon. The structure of compound 6 differs mainly from that of 
5 in the side chain signals because in the 1H NMR spectrum signal at d=3.96 
(m, 1H) and 1.23 (d, 3H, J=6.2 Hz) were observed, indicating the presence of 
secondary alcohol.
 
In the 1H NMR spectrum of compound 7, three signals at d=3.71 (t, 2H, 
J=6.2 Hz); 2.96 (dd, 2H, J=6.4 and J=8.6 Hz) and 1.90 (m, 2H) were assigned 
to the saturated side chain H-3’, H-1’ and H-2’, respectively. On the other 
hand, the MS spectrum from the acetate 10 presented a molpeak at m/z 163 
[M+] (19.9) was observed. 
In the 1H NMR spectrum of isomer 8, the presence of signal at d = 4.11 ppm 
(m, 1H’) was to assigned at carbinolic hydrogen in C-2’ position (secondary 
alcohol). In addition the signal at d=1.31 (d, 3H, J=6.2 Hz) was to assigned an 
terminal methyl group.
Scheme 1. Conditions: a. HNO3/H2SO4 (10:1), HAc (glacial),-10°C, 4h, 
2; 75.0% and 3 5.2%. b. i) BH3·DMS, THF, (2M); N2,-10°C, 15min, and r.t, 
1h; ii) NaBO3·4H2O/ H2O, r.t, 2h; 5; 59.4%; 6; 1.1%; 7; 53.1% and 8; 2.4%. c. 
Ac2O, DMAP, CH2Cl2, 2h, r.t; 10; 95.1%. d. i) AlCl3/CH2Cl2; N2,-10°C, 2h ii) 
H2O, r.t, 18h; 4; 57.4%. e. Ac2O, DMAP, CH2Cl2, 2h, r.t.; 9; 94.3%.
Biological Results  
The in vitro cytotoxic evaluation of safrole 1 and the compounds 2-8 (see 
Scheme 1) indicate that the cell viability expressed as % vs. control vehicle 
(ethanol 1%) for the compounds 3 and 4 was dose-dependant (mM). The IC50 
values of compounds 3, 4, safrole and the reference compound daunorubicin 
are summarized in Table 1 as the micromolar concentration that produces 50% 
cell growth inhibition after 72 hours of drug exposure. The results indicate that 
derivatives 3 and 4 are more toxic than safrole against MCF-7 cells and that 
compound 4, present higher toxicity against all the cancer cells tested than the 
parent compound and the derivative 3. The activity of compounds 2, 5, 6, 7 and 
8 was comparable to that of safrole (data not shown). However, daunorubicin is 
at least one hundred times more active as anticancer compound against MDA-
MD231 cells and 300-500 times more effective towards MCF-7 cells than the 
safrole derivatives 3 and 4. Nevertheless, it is important to emphasize that 
compound 4 has 10 times less cytotoxicity than daunorubicin against normal 
cells, an interesting characteristic. 
Table 1. Cytotoxic activity of synthesized derivatives safrole compounds 
against two breast cancer cell lines, MCF-7, MDA-MB231, one colon cancer 
cell line, DLD-1 and a dermal human fibroblast cells, DHF, expressed as 
inhibitory concentration IC50.
Compounds IC50 (μM)
MCF-7 MDA-MB231 DLD-1 DHF
3 80 + 6.92 > 100 > 100 > 100
4 55.0 + 7,11 37.5 + 2.65 44.0 + 6.92 > 100
Daunorubicin 0.16 + 0.02 0.35 +0.04 0.24 +0.03 12.3 + 1.81
Safrole > 100 > 100 > 100 > 100
Safrole has been shown to become cytotoxic to various human cell types 
at higher concentrations (5–10 mM)19,20. In the other hand our data showed that 
the cytotoxic activity of 3 and 4, is reached at micromolar concentrations, what 
indicates that this derivatives proved to be more toxic than safrole itself against 
the selected cancer cells.
CONCLUSION
In synthetic terms, the classic nitration method used for the synthesis of 
compound 2 led to better yields than those previously reported in literature. An 
increase in the yields of primary alcohols with lower amounts of the secondary 
alcohol was achieved preparing the organoborane complex at -10 ° C, omitting 
the use of solvents and an alkaline environment external to the oxidation process 
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carried out by the sodium per borate in water. The formation of catechols from 
safrol with AlCl3 was favoured by the presence in the molecule of the electron 
attractor group (NO2). The safrole derivatives 3 and 4 proved to be more toxic 
than safrole itself against the selected cancer cells.
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